References
1. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel
coronavirus disease (COVID-19) through postmortem core biopsies.Mod Pathol . Jun 2020;33(6):1007-1014.
doi:10.1038/s41379-020-0536-x
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19
associated with acute respiratory distress syndrome. Lancet Respir
Med . Apr 2020;8(4):420-422. doi:10.1016/s2213-2600(20)30076-x
3. Fei Q, Bentley I, Ghadiali SN, Englert JA. Pulmonary drug delivery
for acute respiratory distress syndrome. Pulm Pharmacol Ther . Jan
19 2023:102196. doi:10.1016/j.pupt.2023.102196
4. De Jong OG, Van Balkom BW, Schiffelers RM, Bouten CV, Verhaar MC.
Extracellular vesicles: potential roles in regenerative medicine.Front Immunol . 2014;5:608. doi:10.3389/fimmu.2014.00608
5. Kaspi H, Semo J, Abramov N, et al. MSC-NTF (NurOwn®) exosomes: a
novel therapeutic modality in the mouse LPS-induced ARDS model.Stem Cell Res Ther . Jan 19 2021;12(1):72.
doi:10.1186/s13287-021-02143-w
6. Krishnan A, Muthusamy S, Fernandez FB, Kasoju N. Mesenchymal Stem
Cell-Derived Extracellular Vesicles in the Management of
COVID19-Associated Lung Injury: A Review on Publications, Clinical
Trials and Patent Landscape. Tissue Eng Regen Med . Apr 6
2022:1-15. doi:10.1007/s13770-022-00441-9
7. Tang Y, Zhou Y, Li HJ. Advances in mesenchymal stem cell exosomes: a
review. Stem Cell Res Ther . Jan 19 2021;12(1):71.
doi:10.1186/s13287-021-02138-7
8. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic
mesenchymal stromal cells for moderate to severe acute respiratory
distress syndrome (START study): a randomised phase 2a safety trial.Lancet Respir Med . Feb 2019;7(2):154-162.
doi:10.1016/s2213-2600(18)30418-1
9.. Sengupta V, Sengupta S, Lazo A, Jr., Hicok KC, Moseley T. Response
to Lim et al. re: ”Exosomes Derived from Bone Marrow Mesenchymal Stem
Cells as Treatment for Severe COVID-19”. Stem Cells Dev . Jul
2020;29(14):879-881. doi:10.1089/scd.2020.0095
10. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes
Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe
COVID-19. Stem Cells Dev . Jun 15 2020;29(12):747-754.
doi:10.1089/scd.2020.0080
11. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells
for treatment of ARDS: a phase 1 clinical trial. Lancet Respir
Med . Jan 2015;3(1):24-32. doi:10.1016/s2213-2600(14)70291-7
12. Zhou T, Yuan Z, Weng J, et al. Challenges and advances in clinical
applications of mesenchymal stromal cells. J Hematol Oncol . Feb
12 2021;14(1):24. doi:10.1186/s13045-021-01037-x